Overview
Glaukos Q3 2025 net sales grow 38% yr/yr, beating analyst expectations, per LSEG data
Adjusted EPS for Q3 2025 also beats analyst expectations
Company raises 2025 net sales guidance, introduces preliminary 2026 guidance
Outlook
Glaukos raises 2025 net sales guidance to $490 mln-$495 mln
Glaukos introduces preliminary 2026 net sales guidance of $600 mln-$620 mln
Result Drivers
GLAUCOMA SALES - Record net sales in glaucoma segment, with U.S. sales increasing 57% yr/yr, driving overall growth
STRATEGIC EXECUTION - Strong momentum attributed to successful execution of strategic plans, per CEO Thomas Burns
PRODUCT PIPELINE - Advancement of novel, dropless platform technologies contributing to improved patient outcomes
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $133.50 mln | $122.50 mln (14 Analysts) |
Q3 Adjusted loss per share | Beat | -$0.16 | -$0.26 (15 Analysts) |
Q3 Adjusted Net loss | Beat | -$9.20 mln | -$14.80 mln (13 Analysts) |
Q3 Net loss | -$16.20 mln | ||
Q3 Gross Margin | 78% | ||
Q3 Adjusted Gross Margin | 84% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Glaukos Corp is $115.00, about 32.4% above its October 28 closing price of $77.79
Press Release: ID:nBwbRXfjza
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)